Victory Capital Management Inc. Acquires 642 Shares of argenx SE (NASDAQ:ARGX)

Victory Capital Management Inc. raised its holdings in argenx SE (NASDAQ:ARGX) by 69.8% in the third quarter, HoldingsChannel.com reports. The firm owned 1,562 shares of the company’s stock after purchasing an additional 642 shares during the quarter. Victory Capital Management Inc.’s holdings in argenx were worth $847,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Perpetual Ltd bought a new stake in shares of argenx during the 3rd quarter worth approximately $76,314,000. Logos Global Management LP bought a new position in argenx in the 2nd quarter valued at approximately $58,055,000. Sei Investments Co. lifted its stake in argenx by 15.2% in the 2nd quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after purchasing an additional 50,477 shares during the last quarter. Tri Locum Partners LP lifted its stake in argenx by 166.5% in the 2nd quarter. Tri Locum Partners LP now owns 74,558 shares of the company’s stock valued at $32,063,000 after purchasing an additional 46,577 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in argenx in the 3rd quarter valued at approximately $15,609,000. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and increased their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Wolfe Research raised shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and upped their price target for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Guggenheim upped their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Evercore ISI upped their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $630.42.

argenx Trading Up 1.2 %

NASDAQ:ARGX opened at $614.59 on Thursday. The stock has a market capitalization of $37.10 billion, a price-to-earnings ratio of -698.40 and a beta of 0.61. The firm has a fifty day simple moving average of $560.78 and a two-hundred day simple moving average of $492.76. argenx SE has a 12 month low of $327.73 and a 12 month high of $620.28.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same period last year, the firm earned ($1.25) earnings per share. Equities analysts predict that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.